Right Nipple Lesion Found in a 43-Year-Old Woman

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Across all 3 treatment arms, global health status/quality of life and functional domains were maintained in the phase 3 EMBER-3 trial.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

PFS was improved with first-line sacituzumab govitecan plus pembrolizumab for patients with PD-L1–positive metastatic TNBC.

Vepdegestrant shows significant clinical activity and a favorable safety profile in ESR1-mutant HER2-negative, ER-positive metastatic breast cancer vs fulvestrant.